Download PDF
Tierarztl Prax Ausg K Kleintiere Heimtiere 2025; 53(03): 146-158
DOI: 10.1055/a-2546-1573
Übersichtsartikel

Oclacitinib – Januskinase-Hemmung in der Veterinärdermatologie

Oclacitinib in dogs – Janus kinase inhibition in veterinary dermatology
Paulina J.C. Popp
1   Kleintierklinik, Ludwig-Maximilians-Universität München
,
Ralf S. Mueller
1   Kleintierklinik, Ludwig-Maximilians-Universität München
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Oclacitinib (Apoquel, Zoetis) ist aktuell der einzige in der EU für die Veterinärmedizin zugelassene Januskinase (JAK)-Inhibitor. Das Medikament ist zugelassen für die Behandlung von atopischer Dermatitis und allergischem Juckreiz des Hundes. Hierfür wird es bereits seit über 10 Jahren sicher und erfolgreich eingesetzt. Weiterhin sind bereits mehrere Fallberichte publiziert, welche nach Ausschöpfung der zugelassenen Medikamente von einem erfolgreichen Off-Label-Einsatz von Oclacitinib insbesondere bei T-Zell-mediierten Krankheitsbildern berichten.

Oclacitinib ist nur für Hunde zugelassen. Von einem Einsatz bei Katzen wird abgeraten, da hierfür nicht genügend Daten aus klinischen Studien vorliegen. Es ist jedoch bekannt, dass diese eine höhere Dosierung benötigen und die therapeutische Breite geringer ist als bei Hunden. In diesem Übersichtsartikel wird eine Zusammenfassung über Studien zur Anwendung von Oclacitinib bei Hunden mit atopischer Dermatitis sowie ein Ausblick zur Verabreichung bei Katzen gegeben. Weiterhin wird eine Übersicht zur erfolgreichen Anwendung von Oclacitinib bei anderen immunmediierten Krankheiten vermittelt.

Abstract

Oclacitinib (Apoquel, Zoetis) is currently the only Janus kinase inhibitor approved for veterinary medicine in the EU. The drug is approved for treatment of atopic dermatitis and associated pruritus in dogs. For this purpose, it has been used safely and successfully for over 10 years. Furthermore, a number of case reports have already been published which report successful off-label use of oclacitinib, particularly in T-cell mediated diseases, after approved drugs were ineffective. Oclacitinib is only approved for dogs. Its use in cats is not recommended as there is insufficient data from clinical trials. However, it is known that cats require a higher dosage and that the drug has less therapeutic safety than in dogs. This review article summarizes studies on the use of oclacitinib in dogs with atopic dermatitis and provides an outlook on its administration in cats. An overview of the successful use of oclacitinib in other immune-mediated diseases is presented.

Schlüsselwörter

Januskinase-Inhibitoren - JAK-STAT-Signalweg - Juckreiz - Allergie - Off-Label-Use

Keywords

Janus kinase inhibitors - JAK-STAT pathway - pruritus - allergy - off-label use


Publication History

Received: 22 December 2024

Accepted: 13 May 2025

Article published online:
13 June 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Miller J, Simpson A, Bloom P. et al. 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines. J Am Anim Hosp Assoc 2023; 59: 255-284
    CrossrefPubMedSearch in Google Scholar
  • 2 Bruet V, Mosca M, Briand A. et al. Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs. Vet Sci 2022; 9
    CrossrefPubMedSearch in Google Scholar
  • 3 Cosgrove SB, Wren JA, Cleaver DM. et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24 587-597 e141-e582
    CrossrefPubMedSearch in Google Scholar
  • 4 Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci 2018; 27: 1984-2009
    CrossrefPubMedSearch in Google Scholar
  • 5 Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol 2017; 76: 736-744
    CrossrefPubMedSearch in Google Scholar
  • 6 Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol 2020; 31: 100-104
    CrossrefPubMedSearch in Google Scholar
  • 7 Yamaoka K, Saharinen P, Pesu M. et al. The Janus kinases (Jaks). Genome Biol 2004; 5: 253
    CrossrefPubMedSearch in Google Scholar
  • 8 Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287
    CrossrefPubMedSearch in Google Scholar
  • 9 Gadina M, Le MT, Schwartz DM. et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford) 2019; 58: i4-i16
    CrossrefPubMedSearch in Google Scholar
  • 10 Eichner A, Wohlrab J. Pharmacology of inhibitors of Janus kinases - Part 1: Pharmacokinetics. J Dtsch Dermatol Ges 2022; 20: 1485-1499
    CrossrefPubMedSearch in Google Scholar
  • 11 Gonzales AJ, Bowman JW, Fici GJ. et al. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37: 317-324
    CrossrefPubMedSearch in Google Scholar
  • 12 Gotthelf Efficacy of APOQUEL® for the Control of Otitis Externa Secondary to Allergic Skin Disease in Client-Owned Dogs. International Journal of Veterinary Health Science and Research. 2017 doi:10.19070/2332-2748-1700041
    CrossrefPubMedSearch in Google Scholar
  • 13 Collard WT, Hummel BD, Fielder AF. et al. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther 2014; 37: 279-285
    CrossrefPubMedSearch in Google Scholar
  • 14 Gonzales AJ, Humphrey WR, Messamore JE. et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013; 24: 48-53 e11-42
    CrossrefPubMedSearch in Google Scholar
  • 15 Cosgrove SB, Wren JA, Cleaver DM. et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114
    CrossrefPubMedSearch in Google Scholar
  • 16 Cosgrove SB, Cleaver DM, King VL. et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol 2015; 26 171-179 e135
    CrossrefPubMedSearch in Google Scholar
  • 17 Denti D, Caldin M, Ventura L, De Lucia M. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Vet Dermatol 2022; 33: 149-e142
    CrossrefPubMedSearch in Google Scholar
  • 18 Gadeyne C, Little P, King VL. et al. Efficacy of oclacitinib (Apoquel(R)) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol 2014; 25 512-518 e586
    CrossrefPubMedSearch in Google Scholar
  • 19 Little PR, King VL, Davis KR. et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2015; 26 23-30 e27-e28
    CrossrefPubMedSearch in Google Scholar
  • 20 Simpson AC, Schissler JR, Rosychuk RAW, Moore AR. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Vet Dermatol 2017; 28: 485-e113
    CrossrefPubMedSearch in Google Scholar
  • 21 Souto A, Salgado E, Maneiro JR. et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015; 67: 117-127
    CrossrefPubMedSearch in Google Scholar
  • 22 EJ High ATHL, L Ferrer. A retrospective study comparing the incidence of cutaneous histiocytoma development in atopic dogs treated with oclacitinib and ciclosporin. Veterinary Dermatology 2017; 28: 426-455
    CrossrefPubMedSearch in Google Scholar
  • 23 Lancellotti BA, Angus JC, Edginton HD, Rosenkrantz WS. Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib. J Am Vet Med Assoc 2020; 257: 507-516
    CrossrefPubMedSearch in Google Scholar
  • 24 Banovic F, Tarigo J, Gordon H. et al. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production. Vet Dermatol 2019; 30: 17-e16
    CrossrefPubMedSearch in Google Scholar
  • 25 Marsella R, Doerr K, Gonzales A. et al. Oclacitinib 10 years later: lessons learned and directions for the future. J Am Vet Med Assoc 2023; 261: S36-S47
    CrossrefPubMedSearch in Google Scholar
  • 26 Favrot C, Bizikova P, Fischer N. et al. The usefulness of short-course prednisolone during the initial phase of an elimination diet trial in dogs with food-induced atopic dermatitis. Vet Dermatol 2019; 30: 498-e149
    CrossrefPubMedSearch in Google Scholar
  • 27 Fischer N, Spielhofer L, Martini F. et al. Sensitivity and specificity of a shortened elimination diet protocol for the diagnosis of food-induced atopic dermatitis (FIAD). Vet Dermatol 2021; 32: 247-e265
    CrossrefPubMedSearch in Google Scholar
  • 28 Forte WC, Sumita JM, Rodrigues AG. et al. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr) 2005; 33: 307-311
    CrossrefPubMedSearch in Google Scholar
  • 29 Olivry T, Lokianskiene V, Blanco A. et al. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis. Vet Dermatol 2023; 34: 99-106
    CrossrefPubMedSearch in Google Scholar
  • 30 Fukuyama T, Ganchingco JR, Baumer W. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib. Eur J Pharmacol 2017; 794: 20-26
    CrossrefPubMedSearch in Google Scholar
  • 31 Nishiyama T, Kusakabe M, Imanishi I. et al. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis. Vet Dermatol 2023; 34: 523-531
    CrossrefPubMedSearch in Google Scholar
  • 32 Ortalda C, Noli C, Colombo S, Borio S. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. Vet Dermatol 2015; 26: 235-e252
    CrossrefPubMedSearch in Google Scholar
  • 33 Ferrer L, Carrasco I, Cristofol C, Puigdemont A. A pharmacokinetic study of oclacitinib maleate in six cats. Vet Dermatol 2020; 31: 134-137
    CrossrefPubMedSearch in Google Scholar
  • 34 Carrasco I, Ferrer L, Puigdemont A. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. J Feline Med Surg 2022; 24: 787-793
    CrossrefPubMedSearch in Google Scholar
  • 35 Lopes NL, Campos DR, Machado MA. et al. A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats. BMC Vet Res 2019; 15: 137
    CrossrefPubMedSearch in Google Scholar
  • 36 Moore A, Burrows AK, Malik R. et al. Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome. Vet Dermatol 2022; 33: 435-439
    CrossrefPubMedSearch in Google Scholar
  • 37 Lappin MR, VanLare KA, Seewald W. et al. Effect of oral administration of cyclosporine on Toxoplasma gondii infection status of cats. Am J Vet Res 2015; 76: 351-357
    CrossrefPubMedSearch in Google Scholar
  • 38 Rosenkrantz WS. Pemphigus: current therapy. Vet Dermatol 2004; 15: 90-98
    CrossrefPubMedSearch in Google Scholar
  • 39 Mueller RS, Krebs I, Power HT, Fieseler KV. Pemphigus foliaceus in 91 dogs. J Am Anim Hosp Assoc 2006; 42: 189-196
    CrossrefPubMedSearch in Google Scholar
  • 40 Olivry T, Linder KE, Banovic F. Cutaneous lupus erythematosus in dogs: a comprehensive review. BMC Vet Res 2018; 14: 132
    CrossrefPubMedSearch in Google Scholar
  • 41 Olivry T. A review of autoimmune skin diseases in domestic animals: I – superficial pemphigus. Vet Dermatol 2006; 17: 291-305
    CrossrefPubMedSearch in Google Scholar
  • 42 Hernandez-Bures A, Bidot WA, Griffin CE, Rosenkrantz WS. The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis. Vet Dermatol 2023; 34: 554-566
    CrossrefPubMedSearch in Google Scholar
  • 43 Carrasco I, Martinez M, Albinyana G. Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. Vet Dermatol 2021; 32: 299-301
    CrossrefPubMedSearch in Google Scholar
  • 44 Bizikova P, Olivry T, Linder K, Rybnicek J. Spontaneous autoimmune subepidermal blistering diseases in animals: a comprehensive review. BMC Vet Res 2023; 19: 55
    CrossrefPubMedSearch in Google Scholar
  • 45 Aymeric E, Bensignor E. A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. Vet Dermatol 2017; 28: 512-e123
    CrossrefPubMedSearch in Google Scholar
  • 46 Harvey RG, Olivri A, Lima T, Olivry T. Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases. Vet Dermatol 2023; 34: 53-58
    CrossrefPubMedSearch in Google Scholar
  • 47 High EJ, Linder KE, Mamo LB. et al. Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs. Vet Dermatol 2020; 31: 330-e386
    CrossrefPubMedSearch in Google Scholar
  • 48 Cain CL. Canine Perianal Fistulas: Clinical Presentation, Pathogenesis, and Management. Vet Clin North Am Small Anim Pract 2019; 49: 53-65
    CrossrefPubMedSearch in Google Scholar
  • 49 Harvey R, Horton H. Successful treatment of perianal fistulas in two dogs with oclacitinib. Vet Dermatol 2023; 34: 483-486
    CrossrefPubMedSearch in Google Scholar
  • 50 Pye C. Canine sebaceous adenitis. Can Vet J 2021; 62: 293-296
    PubMedSearch in Google Scholar
  • 51 Perez-Aranda M, Yotti C, Perez J, Ginel PJ. Successful treatment of sebaceous adenitis with oclacitinib and low-dose prednisolone in a dog. Vet Dermatol 2024; 35: 238-241
    CrossrefPubMedSearch in Google Scholar
  • 52 Aslan J, Shipstone MA, Sullivan LM. Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report. Vet Dermatol 2021; 32: 398-e113
    CrossrefPubMedSearch in Google Scholar
  • 53 Levy BJ, Linder KE, Olivry T. The role of oclacitinib in the management of ischaemic dermatopathy in four dogs. Vet Dermatol 2019; 30: 201-e263
    CrossrefPubMedSearch in Google Scholar
  • 54 Colombo S, Cornegliani L, Vercelli A, Fondati A. Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series. Vet Dermatol 2021; 32: 363-e100
    CrossrefPubMedSearch in Google Scholar
  • 55 Chan T, Koch SN, Devine S, Mendoza-Kuznetsova E. Oclacitinib therapy in two cats with refractory proliferative and necrotising otitis externa. Vet Dermatol 2024; doi:10.1111/vde.13269
    CrossrefPubMedSearch in Google Scholar
  • 56 Mauldin EA, Ness TA, Goldschmidt MH. Proliferative and necrotizing otitis externa in four cats. Vet Dermatol 2007; 18: 370-377
    CrossrefPubMedSearch in Google Scholar
  • 57 Panzuti P, Jongh O, Dony M. et al. Extra-auricular lesions of proliferative and necrotizing otitis externa in three kittens. Vet Dermatol 2021; 32: 385-e110
    CrossrefPubMedSearch in Google Scholar